Back to top anchor

Optimising the potential benefits of lung cancer screening in Māori in New Zealand

Year:
2021
Duration:
36 months
Approved budget:
$1,186,187.75
Researchers:
Professor Dr Sue Crengle
,
Dr Karen Bartholomew
,
Dr Kate Parker
,
Associate Professor Robert Young
,
Dr Rawiri McKree Jansen
,
Ms Raewyn Scott
,
Associate Professor Natalie Walker
,
Dr Sandra Hotu
Health issue:
Respiratory/asthma
Proposal type:
Project
Lay summary
Māori develop lung cancer earlier with higher incidence and mortality than non-Māori. Screening has been shown to reduce mortality through earlier diagnosis and is now recommended for high risk populations in both the USA and Europe. Our Māori-led research team is submitting an application to the HRC Global Alliance for Chronic Diseases Cancer Call proposing a cluster randomised trial of lung cancer screening to test two invitation and risk prediction processes: one based in general practice, the other undertaken centrally. Our programme is focused on designing and robustly testing all components of screening as an intervention to ensure that they can be optimised for Māori. This EOI proposes to add substantial value to our lung cancer screening trial through the inclusion of a nested cohort sub-study on chronic obstructive pulmonary disease (COPD), which will provide a systematic assessment of COPD in Māori screen attendees.